California-based Dr Rath Research Institute, a non-profit organisation dedicated to research and education in natural health worldwide, revealed on Wednesday that a team of its researchers has developed a cancer vaccine to reduce tumour growth.
The institute stated that the peptide-based vaccine targets specific enzymes called metalloproteinases (MMPs). These enzymes are necessary for any cancer to grow tumours, metastasize and form blood vessels in tumours (angiogenesis). Research showed that test mice, vaccinated with peptides containing specific sequences from MMP-2 and MMP-9 and subsequently challenged with melanoma cancer cells, had an average reduction in tumour volume by about 76% compared to unvaccinated controls. It added that some vaccinated animals did not develop any cancer at all.
When compared to monoclonal antibodies (Mabs) or biosimilar molecules recently developed to combat cancer, the anti MMP vaccine approach promises to be much more effective as well as affordable in the global fight against the disease. Mabs/biosimilars are directed against one specific type of cancer, but the anti-MMP vaccine can target all types of the disease at once. Also, while the Mabs/biosimilars usually require an injection once or twice each month, the anti-MMP vaccine would require one single vaccination with potential boosts only after several years.
The Dr Rath Research Institute added that successful development of anti-MMP vaccination means it could be offered to the public by national or international health services at a reasonable cost.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study